Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classifications

Table 6 FAB classification: OS of patients with MDS or AML receiving azacitidine front-line

FAB diagnosis	n	Median OS, mo	95 % CI, mo	p value
AML30+ MDS-RAEB-t MDS-RAEB	111 101 131	10.9 12.8 24.4	7.5–14.3 10.1–15.5 18.5–30.3	<0.001^a
AML30+ MDS-RAEB-t	111 101	10.9 12.8	7.5–14.3 10.1–15.5	0.376
MDS-RAEB-t MDS-RAEB	101 131	12.8 24.4	10.1–15.5 18.5–30.3	<0.001^b

^aHR = 1.248; 95 % CI 1.249, 1.634
^bHR = 2.185; 95 % CI 1.557, 3.066
FAB French-American-British, OS overall survival, MDS myelodysplastic syndrome, AML acute myeloid leukaemia, CI confidence interval, RAEB refractory anaemia with excess blasts, HR hazard ratio

ISSN: 1756-8722